Abstract

It has been reported that about one quarter of long-term nonprogressors had anti-CCR5 antibodies and such antibodies were not found in disease progressing HIV-1 positive individuals [1]. To identify such antibodies we panned an HIV immune library constructed from bone marrow of three long-term nonprogressors against a synthetic sulfated N-terminal CCR5 peptide (2–15) (R5Nt). Twenty anti-CCR5 monoclonal antibodies were selected that bind to the R5Nt and cell-associated CCR5. Sequence analysis revealed that eighteen clones have VHs that were derived from the same germline sequence. Preliminary data showed that these antibodies inhibited primary HIV-1 isolates from clade B and E as tested in a pseudovirus assay. Identification of these anti-CCR5 human monoclonal antibodies indicates possible contribution to mechanisms determining the slow progression or lack of disease in long-term nonprogresssors. The selected anti-CCR5 antibodies may have potentials as therapeutics and/or prophylactics in combination with other HIV-1 neutralizing antibodies and antiretroviral drugs.

Highlights

  • Mei-Yun Zhang*1,2, Bang Vu1, Chih-chin Huang3, Igor Sidirov1, Vidita Choudhly1, Peter D Kwong3 and Dimiter S Dimitrov1

  • It has been reported that about one quarter of long-term nonprogressors had anti-CCR5 antibodies and such antibodies were not found in disease progressing HIV-1 positive individuals [1]

  • To identify such antibodies we panned an HIV immune library constructed from bone marrow of three long-term nonprogressors against a synthetic sulfated N-terminal CCR5 peptide (2–15) (R5Nt)

Read more

Summary

Introduction

Mei-Yun Zhang*1,2, Bang Vu1, Chih-chin Huang3, Igor Sidirov1, Vidita Choudhly1, Peter D Kwong3 and Dimiter S Dimitrov1. Address: 1Center for Cancer Research Nanobiology Program, National Cancer Institute-Frederick, National Institutes of Health, Frederick, Maryland, 21702, USA, 2SAIC-Frederick, Inc., National Cancer Institute-Frederick, National Institutes of Health, Frederick, Maryland, 21702, USA and 3Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, 20892, USA * Corresponding author from 2006 International Meeting of The Institute of Human Virology Baltimore, USA.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call